Search HDBuzz

Huntington’s disease therapeutics conference 2023 - Day 3

Huntington’s disease therapeutics conference 2023 - Day 3

Check out research updates from Day 3 of the 2022 HD Therapeutics Conference #HDTC2023

Joel Stanton, Dr Rachel Harding, Dr Leora Fox, and Dr Tamara MaiuriMay 22, 2023

Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials

Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials

Both PTC Therapeutics and uniQure have shared updates from their respective clinical trials, testing different huntingtin-lowering approaches. We explore the data presented from both of these studies and what this means for HD family members.

Dr Leora Fox and Dr Rachel HardingJune 21, 2023

Tipping the balance; new insights into HD genetic modifiers

Tipping the balance; new insights into HD genetic modifiers

A new study from researchers at Thomas Jefferson University delves into the details of how genetic modifiers of Huntington’s disease work.

Dr Rachel HardingSeptember 01, 2023

Could halting CAG expansions be a new treatment for HD?

Could halting CAG expansions be a new treatment for HD?

The gene MSH3 is getting a lot of attention in HD research lately. New findings suggest MSH3 lowering could halt CAG repeat expansions, offering a new therapeutic avenue.

Dr Sarah HernandezOctober 05, 2023

Getting to the Root of Huntington's Disease: A Plant-Based Approach

Getting to the Root of Huntington's Disease: A Plant-Based Approach

Researchers used plants to study how to stop the Huntington’s disease protein from forming toxic clumps

Dr Rachel HardingOctober 15, 2023

Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD

Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD

The HD pipeline is rich and varied. Let's talk about some out-of-the-box approaches for developing drugs for HD that don't involve huntingtin lowering.

Kelly AndrewNovember 24, 2023

CRISPR-based drugs: one giant leap for mankind

CRISPR-based drugs: one giant leap for mankind

Casgevy is the first CRISPR-based drug to make its way through the approval process, all but curing Sickle Cell Disease and it’s paving the way for similar drugs targeting other diseases. Is Huntington’s disease next?

Dr Sarah HernandezFebruary 14, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 1

Huntington's Disease Therapeutics Conference 2024 - Day 1

Check out research updates from Day 1 of the 2024 HD Therapeutics Conference #HDTC2024

Dr Leora Fox, Dr Rachel Harding, and Dr Sarah HernandezMarch 05, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 2

Huntington's Disease Therapeutics Conference 2024 - Day 2

Dr Leora Fox, Dr Sarah Hernandez, and Dr Rachel HardingMarch 06, 2024

The director’s cut: how CAG repeats change the editing of genetic messages

The director’s cut: how CAG repeats change the editing of genetic messages

Scientists in Massachusetts have recently advanced our understanding of how repetitive sequences in DNA can disrupt the creation and editing of genetic messenger molecules in cells, and how this could lead to the production of harmful proteins.

Lucy CouplandMarch 26, 2024

You can also read About HDBuzz for information on HDBuzz or try your search on a search engine.

Donate

Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community.

With your support, we can ensure the continuity of our services. Nothing is expected, but everything is appreciated and sustains what we do at HDBuzz. Please consider giving what you're able. More information...